<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502500</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0019</org_study_id>
    <nct_id>NCT02502500</nct_id>
  </id_info>
  <brief_title>Effect of AKB-6548 on the Pharmacokinetics of Celecoxib</brief_title>
  <official_title>An Open-label Study in Healthy Subjects to Assess the Effect of Once-daily Multiple Dosing of AKB-6548 on the Pharmacokinetics of the CYP2C9 Substrate Celecoxib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the single dose pharmacokinetics (PK) of celecoxib in healthy subjects when
      administered alone and following multiple daily doses of AKB-6548.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the single dose plasma pharmacokinetics (PK), safety, and tolerability of celecoxib
      in healthy subjects with CYP2C9 extensive metabolizer (EM) genotype when administered alone
      and following multiple daily doses of AKB-6548.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters (Cmax)</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
    <description>maximum observed plasma concentration (Cmax) for celecoxib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (time to reach Cmax )</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
    <description>time to reach Cmax for celecoxib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (t½)</measure>
    <time_frame>from pre-dose to 48 hours post-dose</time_frame>
    <description>terminal elimination half-life (t½) for celecoxib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (AUC0-t)</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
    <description>concentration (AUC0-t) for celecoxib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (area under the plasma concentration-time curve from 0 to last quantifiable)</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
    <description>area under the plasma concentration-time curve from 0 to last quantifiable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (AUC0-inf)</measure>
    <time_frame>from pre-dose to 48 hours post-dose</time_frame>
    <description>AUC from time 0 to infinity (AUC0-inf) for celecoxib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (CL/F)</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
    <description>apparent oral clearance (CL/F) for celecoxib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters (Vz/F)</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
    <description>apparent volume of distribution during the terminal phase (Vz/F) for celecoxib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability will be measured by vital signs</measure>
    <time_frame>up to ten days</time_frame>
    <description>The safety and tolerability of the single doses of celecoxib alone and in combination with AKB-6548 will be monitored for vital signs, clinical laboratory assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability will be monitoring of adverse events (AEs)</measure>
    <time_frame>up to ten days</time_frame>
    <description>The safety and tolerability of the single doses of celecoxib alone and in combination with AKB-6548 will be monitored for adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability will be measured by clinical assays</measure>
    <time_frame>up to ten days</time_frame>
    <description>The safety and tolerability of the single doses of celecoxib alone and in combination with AKB-6548 will be monitored for clinical laboratory assays</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKB-6548 and Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AKB-6548; celecoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_label>AKB-6548 and Celecoxib</arm_group_label>
    <other_name>CELEBREX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKB-6548</intervention_name>
    <arm_group_label>AKB-6548 and Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between 18 and 55 years of age, inclusive, and with a body mass
             index between 18 and 30 kg/sq.meters, inclusive.

          -  Subjects with the following genotype based upon pharmacogenetic testing results:
             CYP2C9 EM: *1*1.

        Exclusion Criteria:

          -  Current or past history of cardiovascular, cerebrovascular, pulmonary, renal or liver
             disease.

          -  Positive serology results for HBsAg, HCV, and HIV at Screening.

          -  Significant renal impairment as evidenced by an estimated glomerular filtration rate
             (eGFR) of &lt;65 mL/minute/1.73 sq.meters.

          -  Known hypersensitivity to celecoxib or sulfonamides.

          -  History of asthma, urticaria, or other allergic-type reactions after taking aspirin or
             other NSAIDs.

          -  Known active cancer or history of chemotherapy use within the previous 24 months.

          -  Current or past history of gastric or duodenal ulcers or other diseases of the GI
             tract (including gastric bypass surgeries) that could interfere with absorption of
             study drug.

          -  Current or past history of gastrointestinal bleeding.

          -  Any history of alcohol or drug abuse within the previous year prior to Screening.

          -  Subjects with a known history of smoking and/or have used nicotine or nicotine
             containing products within the past 6 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akshay Buch</last_name>
    <role>Study Chair</role>
    <affiliation>Akebia Therapeutics Inc.</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

